Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
Ashraf Badros(University of Maryland, Baltimore), Steven Grant(Virginia Commonwealth University)
Cited by 230
Related Papers
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation
|Journal of Biological Chemistry|2005|284
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
|The Lancet Oncology|2023|120
The Bruton tyrosine kinase (<scp>BTK</scp>) inhibitor <scp>PCI</scp>‐32765 synergistically increases proteasome inhibitor activity in diffuse large‐B cell lymphoma (<scp>DLBCL</scp>) and mantle cell lymphoma (<scp>MCL</scp>) cells sensitive or resistant to bortezomib
|British Journal of Haematology|2013|84